Japan has selected three candidates for Covid-19 treatments to receive subsidies for clinical trials, according to the health ministry.

According to Reuters, the drugs include AstraZeneca Plc's antibody treatment AZD7442, Shionogi & Co's protease inhibitor S-217622 and Fujifilm Holding Corp's antiviral favipiravir, known commercially as Avigan.